AMGN · News · 20260908N

Olpasiran Pipeline Risk

AMGEN INC · 2026-09-08 · Importance 37 · Surprise 42

Novartis' Phase 3 pelacarsen trial failed to reduce cardiovascular events despite lowering lipoprotein(a), raising uncertainty for Amgen's comparable olpasiran program. Third-party reports said the result challenged the broader hypothesis that Lp(a) lowering will translate into fewer cardiovascular events. The setback contributed to a roughly 10% decline in Amgen shares on September 8, although the price movement itself is not treated as the topic's financial impact.

Key facts

• Amgen's shares dropped by 4.7% in premarket trading following Novartis' announcement of a Phase III trial failure for pelacarsen and a downgrade from BMO Capital. source